Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 6, 2023

Strategies to Manage Medication Costs and Waste

Russell P. Gollard, MD, FACP, discusses strategies for mitigating the high costs of expensive medications, addressing concerns of medication waste and hoarding.

Episodes in this series

EP. 1 Management Insights for Patients With Hemophilia

EP. 1 Management Insights for Patients With Hemophilia

EP. 2 Coverage Decisions for Expensive Hemophilia Treatments

EP. 2 Coverage Decisions for Expensive Hemophilia Treatments

EP. 3 Impact of ICER Reports on Hemophilia Treatment Decisions

EP. 3 Impact of ICER Reports on Hemophilia Treatment Decisions

EP. 4 Enhancing Provider Access and Expertise for Rare Disease Care

EP. 4 Enhancing Provider Access and Expertise for Rare Disease Care

EP. 5 Factors Impacting Hemophilia A Care Costs

EP. 5 Factors Impacting Hemophilia A Care Costs

EP. 6 Collaborative Strategies in Hemophilia A Care Cost Management

EP. 6 Collaborative Strategies in Hemophilia A Care Cost Management

EP. 7 Strategies to Manage Medication Costs and Waste

EP. 7 Strategies to Manage Medication Costs and Waste

EP. 8 Adapting to Novel Hemophilia A Treatments

EP. 8 Adapting to Novel Hemophilia A Treatments

EP. 9 Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP. 9 Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP. 10 Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP. 10 Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP. 11 Hemophilia A Treatment Factors and Outcomes

EP. 11 Hemophilia A Treatment Factors and Outcomes

EP. 12 Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP. 12 Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP. 13 Consequences of Nonadherence in Hemophilia A

EP. 13 Consequences of Nonadherence in Hemophilia A

EP. 14 Advancements in Hemophilia A Therapies

EP. 14 Advancements in Hemophilia A Therapies

EP. 15 Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP. 15 Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP. 16 Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP. 16 Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP. 17 Emicizumab Dosing: Prophylaxis and Bleeding Management

EP. 17 Emicizumab Dosing: Prophylaxis and Bleeding Management

EP. 18 Optimizing Hemophilia Treatment: Strategies and Adherence

EP. 18 Optimizing Hemophilia Treatment: Strategies and Adherence

EP. 19 Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP. 19 Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP. 20 Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

EP. 20 Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 20th 2026

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

ByNadege Gunn, MD

July 17th 2026

Navigating Treatment Sequencing and Defining Failure in Moderate-to-Severe Atopic Dermatitis

ByAngela J. Lamb, MD

July 17th 2026

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

ByNadege Gunn, MD

July 17th 2026

Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Acalabrutinib-Venetoclax Combos Improve QOL, Safety by Age in CLL

Adequate Biomarker Testing Remains Key Gap in Community Oncology Care: Urs Weber, MD